Last10K.com

Aerpio Pharmaceuticals, Inc. (ARPO) SEC Filing 10-Q Quarterly report for the period ending Friday, June 30, 2017

SEC Filings

Aerpio Pharmaceuticals, Inc.

CIK: 1422142 Ticker: ARPO

Exhibit 99.1

 

LOGO

Aerpio Reports First Quarter 2017 Financial Results

May 16, 2017 08:00 AM Eastern Daylight Time

CINCINNATI—(BUSINESS WIRE) Aerpio Pharmaceuticals, Inc. (“the Company”), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today reported financial results for the first quarter ended March 31, 2017.

“In the first quarter, we announced our $40 million private placement and completed our reverse merger transaction,” said Joseph H. Gardner, CEO of Aerpio. “This new capital enables us to further the development of our product candidates, including the initiation of our planned Phase 2b clinical trial of AKB-9778 in patients with moderate to severe diabetic retinopathy. We look forward to the progress of this trial.”

Financial Highlights

As of March 31, 2017, the Company had cash and cash equivalents and short term investments of $35.2 million, compared to $1.6 million as of December 31, 2016. During the three months ended March 31, 2017, the Company received net proceeds of $37.2 million from the previously announced March 2017 financing as well as $0.3 million in January from an extension to the Aerpio senior secured convertible note financing in March 2016.

The following table summarizes our results of operations for the periods presented:

 

     Three Months Ended March 31,  
     2017      2016  

Operating expenses:

     

Research and development

   $ 2,255,584      $ 2,989,558  

General and administrative

     2,504,001        1,215,885  
  

 

 

    

 

 

 

Total operating expenses

     4,759,585        4,205,443  
  

 

 

    

 

 

 

Operating loss

     (4,759,585      (4,205,443

Grant income

     35,657        8,670  

Interest (expense) income, net

     (271,775      1,078  

Other income, net

     —          997  
  

 

 

    

 

 

 

Total other (expense) income, net

     (236,118      10,745  
  

 

 

    

 

 

 

Net loss and comprehensive loss

   $ (4,995,703    $ (4,194,698
  

 

 

    

 

 

 


The following information was filed by Aerpio Pharmaceuticals, Inc. (ARPO) on Tuesday, May 16, 2017 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Aerpio Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Aerpio Pharmaceuticals, Inc..

Continue

Assess how Aerpio Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Aerpio Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2017 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Condensed Consolidated Balance Sheets (parenthetical) (unaudited)
Condensed Consolidated Balance Sheets (unaudited)
Condensed Consolidated Statements Of Cash Flows (unaudited)
Condensed Consolidated Statements Of Operations And Comprehensive Loss (unaudited)
Condensed Consolidated Statements Of Stockholders Equity (deficit)
Accounts Payable And Accrued Expenses
Accounts Payable And Accrued Expenses (details)
Accounts Payable And Accrued Expenses (tables)
Commitments And Contingencies
Commitments And Contingencies (detail)
Commitments And Contingencies (tables)
Commitments And Contingencies - Additional Information (detail)
Common Stock
Common Stock - Additional Information (detail)
Employee Stock Purchase Plan
Employee Stock Purchase Plan - Additional Information (detail)
Income Taxes
Income Taxes - Additional Information (detail)
Nature Of Organization And Operations
Nature Of Organization And Operations - Additional Information (detail)
Net Loss Per Share
Net Loss Per Share (detail)
Net Loss Per Share (tables)
Notes Payable To Investors
Notes Payable To Investors - Additional Information (detail)
Preferred Stock
Preferred Stock - Additional Information (detail)
Related-party Arrangements
Related-party Arrangements (detail)
Related-party Arrangements (tables)
Schedule Of Weighted Average Common Stock Equivalents Were Excluded From Calculation Of Diluted Net Loss Per Share (detail)
Stock-based Compensation
Stock-based Compensation (tables)
Stock-based Compensation - 2 (detail)
Stock-based Compensation - 3 (detail)
Stock-based Compensation - 4 (detail)
Stock-based Compensation - Additional Information (detail)
Stock-based Compensation - Stock Options Valuation Assumptions (detail)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (detail)
Summary Of Significant Accounting Policies (policies)
Summary Of Significant Accounting Policies (tables)
Summary Of Significant Accounting Policies - Additional Information (detail)

Material Contracts, Statements, Certifications & more

Aerpio Pharmaceuticals, Inc. provided additional information to their SEC Filing as exhibits

Ticker: ARPO
CIK: 1422142
Form Type: 10-Q Quarterly Report
Accession Number: 0001564590-17-017234
Submitted to the SEC: Thu Aug 10 2017 4:05:32 PM EST
Accepted by the SEC: Thu Aug 10 2017
Period: Friday, June 30, 2017
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/arpo/0001564590-17-017234.htm